DeepMed Research

IONIS PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Private, Subsidiary

Established: 1989-01-01

Employees: 927

Market Cap: -

Website: http://www.ionis.fr

Clinical Trials

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease

Phase 1

Completed

Conditions: Huntington's Disease

Interventions: Drug: ISIS 443139 10 mg
Drug: ISIS 443139 30 mg
Drug: ISIS 443139 60 mg
Drug: ISIS 443139 90 mg
Drug: ISIS 443139 120 mg
Other: Placebo

First Posted Date: 2015-08-10

Last Posted Date: 2019-05-31

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 46

Registration Number: NCT02519036

Locations: 🇬🇧
University College London, London, United Kingdom
🇩🇪
Ulm University Hospital, Ulm, Germany
🇬🇧
Cambridge University Hospital, Cambridge, United Kingdom

and more 6 locations

A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: ISIS-FGFR4RX
Drug: Placebo

First Posted Date: 2015-06-19

Last Posted Date: 2018-06-25

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 13

Registration Number: NCT02476019

Locations: 🇺🇸
Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)

Phase 1

Completed

Conditions: Elevated Lipoprotein(a)

Interventions: Drug: Sterile Normal Saline (0.9% NaCl)
Drug: IONIS-APO(a)-LRx

First Posted Date: 2015-04-13

Last Posted Date: 2018-12-05

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 60

Registration Number: NCT02414594

Locations: 🇨🇦
Clinical Site, Toronto, Ontario, Canada

A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1

Phase 1

Completed

Conditions: Myotonic Dystrophy Type 1

Interventions: Drug: Placebo
Drug: IONIS-DMPKRx

First Posted Date: 2014-12-09

Last Posted Date: 2022-12-06

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 48

Registration Number: NCT02312011

Locations: 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸
Kennedy Krieger Institute, Baltimore, Maryland, United States

and more 5 locations

The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia

Phase 3

Completed

Conditions: Hypertriglyceridemia

Interventions: Drug: Placebo
Drug: Volanesorsen

First Posted Date: 2014-11-24

Last Posted Date: 2022-04-13

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 114

Registration Number: NCT02300233

Locations: 🇬🇧
IONIS Investigative Site, Peterborough, United Kingdom

The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome

Phase 3

Completed

Conditions: Familial Chylomicronemia Syndrome

Interventions: Drug: Placebo
Drug: Volanesorsen

First Posted Date: 2014-08-07

Last Posted Date: 2022-04-13

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 67

Registration Number: NCT02211209

Locations: 🇬🇧
IONIS Investigative Site, Peterborough, United Kingdom

Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

Phase 3

Completed

Conditions: Familial Amyloid Polyneuropathy
Transthyretin
Amyloidosis
FAP
TTR

Interventions: Drug: Inotersen

First Posted Date: 2014-06-26

Last Posted Date: 2023-11-18

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 135

Registration Number: NCT02175004

Locations: 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸
Johns Hopkins University Bayview Medical Center, Baltimore, Maryland, United States
🇧🇷
AACD, Sao Paulo, Brazil

and more 19 locations

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)

Phase 2

Completed

Conditions: Elevated Lipoprotein(a)

Interventions: Drug: Placebo
Drug: ISIS-APO(a)Rx

First Posted Date: 2014-06-11

Last Posted Date: 2019-12-20

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 64

Registration Number: NCT02160899

Locations: 🇩🇪
Otto-von Guericke Universitaet, Uniklinik Magdeburg, Magdeburg, Germany
🇬🇧
Newcastle Upon Tyne Hospitals, Newcastle Upon Tyne, United Kingdom
🇬🇧
Barlow Medical Centre, Manchester, United Kingdom

and more 10 locations

Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: ISIS-GCCRRx

First Posted Date: 2013-10-24

Last Posted Date: 2015-05-13

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 38

Registration Number: NCT01968265

Locations: 🇿🇦
Isis Investigative Site, Somerset West, Western Cape, South Africa
🇷🇴
Isis Investigative site, Bucharest, Romania

Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes

Phase 2

Completed

Conditions: Obese
Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: ISIS-PTP1BRx
Drug: daily OAD (metformin and/or sulfonylurea)

First Posted Date: 2013-08-08

Last Posted Date: 2015-03-03

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 92

Registration Number: NCT01918865

Locations: 🇿🇦
Isis Investigational Site, Pretoria, South Africa
🇨🇦
Isis Investigative Site, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy